Correlation of Sonographic Morphologic Index and CA-125 in Predicting the Nature of Ovarian Tumor

Poonam Gusain¹, *Suniti Joshi Rawal², Sharma Paudel³

¹Resident, ²Associate Professor, Department of Obstetrics and Gynecology, Tribhuvan University Teaching Hospital (TUTH), Maharajgunj, Kathmandu
³Associate Professor, Department of Radiology, TUTH, Maharajgunj, Kathmandu

*Corresponding Author:
Dr. Suniti Joshi Rawal
Email: sunudinurawal@yahoo.com

ABSTRACT

Introduction: Ovarian tumor is a group of disease that originates in the ovaries or in the related areas of the fallopian tubes and the peritoneum. Ovarian cancer causes more deaths than any other cancer of the female reproductive system. This study was undertaken to evaluate the efficacy of Sonographic Morphology Index (MI) and CA-125 levels in predicting malignancy in patients with ovarian tumors.

Methods: This study was conducted between April 2016 till April 2017 in the Department of Obstetrics and Gynaecology and Radiology of Tribhuvan University Teaching Hospital. During this period, 106 women with ovarian tumors fulfilling inclusion criteria were taken into the study. CA-125 levels measured and MI scoring was done. The diagnosis made with MI score and CA-125 score were then compared with histopathology report.

Results: Among the 106 studied cases (N=106), 88 (83.01%) had benign and 18 (16.98%) had malignant ovarian tumors. Negative Predictive Value (NPV) and sensitivity of CA-125 for ovarian tumor was 94.10% and 77.77% respectively with accuracy of 73.58%. Sensitivity and NPV of MI score was 100% with accuracy of 84.9% in predicting nature of ovarian tumors. Pearson’s correlation coefficient was 0.216 which showed a positive correlation between MI and CA-125 in predicting nature of ovarian tumors.

Conclusion: The Sonographic MI system is an accurate and simple method to differentiate a malignant tumor from a benign ovarian tumor. The accuracy of the Sonographic MI system improved when the serum CA-125 level was also considered along.

Keywords: CA-125, Ovarian tumors, Sonographic Morphology Index

How to cite this article?

Received: 9 Oct., Accepted: 12 Nov., Published: 11 Dec. 2019
Conflict of Interest: None, Source of Support: None
INTRODUCTION

Ovarian tumor constitute 23% of all gynecologic tumors with ovarian carcinoma being the seventh most common female cancer. Ovarian cancer is the 5th leading cause of deaths in women exceeded only by breast, lung, colon and uterine malignancies. More than 80% of patients who present with advanced disease have 5 year survival rates between 15% and 45%. In contrast the survival rate for stage I disease with malignancy confined to the ovary is around 95%. Ovarian tumors are generally difficult to detect till they are in a clinically advanced stage or have attained a considerable large size to manifest symptoms. As a result there has been increased interest in development of methods that can detect ovarian cancer in early stage when it is curable.

CA-125 has been the most widely used biomarker to evaluate a woman with an ovarian tumor. It is a high molecular weight glycoprotein antigen expressed by coelomic epithelial lining cells and determined by monoclonal antibody. CA-125 is elevated in over 80% of patients with ovarian cancer. In most laboratories, the normal value is 0 to 35 units/ml. Morphological Index (MI) is based on the real time ultrasound and detects altered ovarian morphology. De Priest et al in 1993 developed Morphology Index (MI) based on morphologic characteristics of ovarian tumors. Studies have concluded that a combined strategy of imaging with biomarker was superior to either one alone. When CA-125 and ultrasonography were considered together, specificity increased to 99.8%.

This study was conducted to evaluate the efficacy of Sonographic Morphology Index (MI) and CA-125 levels in predicting malignancy in patients with ovarian tumors so that frequent use of CT scans could be avoided in a low resource setting and help in better management and survival.

MATERIALS AND METHODS

This was a prospective study done in Department of Obstetrics and Gynecology and Radiology, Tribhuvan University Teaching Hospital, Kathmandu Nepal, from 13th April 2016 till 12th April 2017. Approval of the study was taken from Institutional Review Board of Institute of Medicine, Research Department. Purposive sampling was done and sample size of 100±10 was calculated based on statistics of previous year. All women with ovarian tumor irrespective of age and menopausal status undergoing surgery in the research institute were included in the study. Any known case of ovarian carcinoma or already operated for ovarian carcinoma, any other adnexal mass other than ovarian pathalogy, dermoid or germ cell tumor confirmed by histopathology, when CA-125 levels were not available preoperatively or when MI score couldnot be calculated were excluded from the study.

Patients admitted in Female Surgical ward with a diagnosis of ovarian tumor were taken into account every day and history and socio demographic profile of the cases were documented. Patients were counseled as to the implications and limitations of such investigation. An informed consent was obtained from all patients and only those patients who gave consent were included in the study. CA-125 levels were measured preoperatively in all women admitted in ward with a diagnosis of ovarian tumor. CA-125 level < 35 units/ml were labeled as benign and ≥ 35 units/ml were labeled as malignant.

The patients were then subjected to ultrasound and three dimensional size and structure of ovarian tumor was noted. Volume of ovarian tumor was calculated by Prolate ellipsoid formula (Volume of ovarian tumor = length × width × height × 0.523). MI score was calculated by adding volume score (Table 1) and structure score (Table 2). MI score < 5 was labelled benign &≥ 5 was labelled malignant. At the end MI score and CA-125 level were compared with histopathology report. Sensitivity, specificity, Negative Predictive Value, Positive Predictive Value and accuracy were calculated each for CA-125 & MI score. Chi-square (x2) test was used. Confidence interval of 95% was taken and P value of < 0.05 was regarded as statistically significant.
## RESULTS

During the study period, there were a total of 145 ovarian tumor cases at TUTH, out of which 106 (73.1%) were included and 39 (26.89%) were excluded from the study. Among 106 cases 88 (83.01%) were benign and 18 (16.98%) were malignant. Out of 39 excluded cases, 34 cases were teratoma, 2 cases of paratubal cyst, 2 cases of germ cell tumor and 1 was a known case of ovarian tumor.

The most common benign tumor was endometriotic cyst (N= 32, 36.36%) followed by serous cystadenoma (N=22, 25%). Out of 18 malignant tumors, maximum 14 (77.77%) were mucinous cystadenocarcinoma.

### Table 5: Structure score of ovarian tumors

<table>
<thead>
<tr>
<th>Ovarian tumor structure</th>
<th>Structure score</th>
<th>Total number of ovarian tumor (106)</th>
<th>Benign</th>
<th>Malignant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smooth wall + sonolucent</td>
<td>0</td>
<td>16</td>
<td>16 (100%)</td>
<td>0</td>
</tr>
<tr>
<td>Smooth wall, diffuse echogenicity</td>
<td>1</td>
<td>37</td>
<td>37 (100%)</td>
<td>0</td>
</tr>
<tr>
<td>Wall thickening, &lt;3mm fine septa</td>
<td>2</td>
<td>34</td>
<td>32 (94.11%)</td>
<td>2 (5.8%)</td>
</tr>
<tr>
<td>Papillary projection, &gt;3mm</td>
<td>3</td>
<td>6</td>
<td>2 (33.33%)</td>
<td>4 (66.66%)</td>
</tr>
<tr>
<td>Complex cyst, predominantly solid component</td>
<td>4</td>
<td>7</td>
<td>1 (14.28%)</td>
<td>6 (85.71%)</td>
</tr>
<tr>
<td>Complex cyst, solid areas, extratumoral fluid</td>
<td>5</td>
<td>6</td>
<td>0</td>
<td>6 (100%)</td>
</tr>
</tbody>
</table>

P-value for CA-125 was < 0.001.
Sixteen (100%) ovarian tumors with smooth wall and sonoluent echogenicity and 37 (100%) with diffuse echogenicity were all benign in nature. Complex ovarian tumors (N = 6,100%) with solid areas and extratumoral fluid were 100% malignant.

<table>
<thead>
<tr>
<th>Test positive (MI ≥ 5)</th>
<th>Test negative (MI &lt; 5)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease positive (malignant)</td>
<td>18</td>
<td>0</td>
</tr>
<tr>
<td>Disease negative (benign)</td>
<td>16</td>
<td>72</td>
</tr>
<tr>
<td>Total</td>
<td>34</td>
<td>72</td>
</tr>
</tbody>
</table>

Sensitivity = TP/ TP + FN = 1.000
Specificity = TN/ TN + FP = 0.818
PPV = TP/ TP + FP = 0.529
NPV = TN/ TN + FN = 1.000
Accuracy = (TP + TN)/ (TP + TN + FN + FP) = 0.849

*P* value for MI was 0.001

**DISCUSSION**

In our study with a cut off value of 35 units/ml, the sensitivity, specificity, PPV and NPV of CA-125 were 0.777, 0.727, 0.368, 0.941 respectively. Similar finding was noted by Olivier et al.\(^\text{11}\) and by Morgante et al.\(^\text{12}\) In this study ovarian tumors having smooth wall and sonoluent or diffuse echogenicity were 100% (N=16 and N=37 respectively) benign in nature. Complex ovarian tumors with solid areas and extratumoral fluid were 100% (N=6) malignant though one out of seven (14.28%) ovarian tumors with complex structure and predominantly solid component was histologically benign. Around 66.66% (4) of tumors with papillary projection (>3mm) were malignant. This implies that papillary projection >3mm is an important feature of malignancy.

Our finding is consistent with study done by Ueland et al\(^\text{6}\) where 100% of ovarian tumors having smooth wall and sonoluent echogenicity were benign and 98% with diffuse echogenicity were benign. Ovarian tumors with fine papillary projection < 3mm were benign (32, 94%) in index study, finding that was similar to study done by Ueland et al\(^\text{6}\) reporting 95% cases to be benign.

In the index study ovarian tumors having MI score ≤ 5, were all benign and tumors having MI score 9 or 10 were all malignant. Tumors with MI score 6 or 7 had 50% benign and 50% malignant tumors. These results were similar to a study done by DePriest et al.\(^\text{10}\) in which 80 (100%) tumors having MI score <5 were all benign and 13 (32%) of cases having MI ≥5 had ovarian cancer.

In the present study sensitivity, specificity, PPV, NPV and accuracy of MI score for predicting malignancy in ovarian tumors was 1.00, 0.818, 0.529, 1.00 and 0.849 respectively. Similar results were observed by Sassone et al.\(^\text{13,14}\)

**CONCLUSION**

This study shows that the Sonographic Morphologic Index has high efficacy in predicting the nature of ovarian tumors as compared with CA-125 with an accuracy of 84.9% and NPV 100% as compared with CA-125.

**REFERENCES**


